65,437 trials
Low Back Pain
Primary: Tolerability of Electrical Stimulation (NMES) — 0; 5; 8; 0 Participants
Stroke · Hemiparesis · Lower Extremity Paresis
Primary: Change in Lower Extremity Fugl-Meyer Score at End of Treatment — 0.93; 1.8 units on a scale
Sarcoma
Primary: Patients With Response (Confirmed Complete, and Partial) With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor When Treated With Erlotinib. — 0…
Graves' Disease
Primary: Dosimetry Studies
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Adenocarcinoma
Primary: Progression-free Survival > 6 Months — 30.2 percentage of participants
Tachyarrhythmias · Heart Failure · Ventricular Dysfunction
Primary: Percentage of Subjects Who Are Inappropriate Shock Free — 98.5; 97.5 percentage of patients
Breast Carcinoma · Pain · Radiation-Induced Dermatitis
Primary: Mean Radiation Dermatitis Severity (RDS) Score. Range: 0 (no Dermatitis) - 4 (Violaceous Erythema With Diffuse Desquamation Occurring in Sheets; Patchy Crusting…
Brain and Central Nervous System Tumors
Primary: Overall Survival Rate at 3 Years — 73.1 percentage of participants — p=<0.001
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 97.8; 90.1 percentage of participants
Loss of Teeth Due to Extraction
Primary: Radiographic Bone Changes — -1.12; -2.60; -1.16; -.158 millimeter
Diabetes Mellitus · Depression
Primary: Change in Hemoglobin A1C — 9.2; 9.3; 9.1; 8.7 percentage of glycated hemoglobin
Cystic Fibrosis · Advanced Lung Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 43; 18 Participants
Alcohol Dependence · Insomnia
Primary: Percentage of Total Sleep Time in Stage 2 Sleep Pre- and Post-study Medication (Stage 2 Percent) — 51.3; 53.8; 50.2; 59.6 percentage of total sleep time
Nonhematologic Malignancies · Lymphoma
Primary: Cmax: Maximum Observed Plasma Concentration for Ixazomib — 38.975; 39.250; 61.866; 71.949 nanogram per milliliter (ng/mL)
Post-ERCP Acute Pancreatitis
Primary: Number of Patients Who Developed Post-ERCP Pancreatitis — 31; 32 Participants